Physitrack: Strong Finish to the Year, well positioned for 2025 - Redeye

Physitrack’s Q4 2024 report came in stronger on sales than expected but slightly below profitability due to a higher-than-anticipated cost base. Wellness returned to sequential growth, while Lifecare continued its solid performance. Cost efficiencies should support margin expansion, with adjusted EBITDA expected to reach 30% in 2025. Management sees no need for external funding, reinforcing financial stability. Additionally, 2025 appears to be off to a strong start, with positive deal flow and business momentum.

Länk till analysen i sin helhet: https://www.redeye.se/research/1085391/physitrack-strong-finish-to-the-year-well-positioned-for-2025?utm_source=finwire&utm_medium=RSS